CALCULATION OF INDIVIDUAL RISK OF TYPE 2 DIABETES IN PATIENTS WITH GOUT Russian patent published in 2023 - IPC A61B5/00 G01N33/49 A61B5/107 

FIELD: medicine; rheumatology.

SUBSTANCE: in a patient with gout who does not have T2DM and who has applied to a primary care physician or rheumatologist, data on anamnesis, complaints and examination are collected, and fasting serum uric acid (UA) is measured. Further, the required data are encoded: at the level of MK ≥ 480 µmol/l 1 point is assigned, at the value of <480 µmol/l 0 points are assigned, after calculating the body mass index (BMI) when a BMI > 30 kg/m² is detected 1 point is assigned, with a BMI value < 30 kg/m² 0 points are assigned, if tophi is detected 1 point is assigned, in the absence of tophi 0 points are assigned, in the presence of arterial hypertension (AH) 1 point is assigned, in the absence of AH 0 points are assigned, in the presence of DM2 in relatives of the first line of kinship 1 point is assigned, in the absence of DM2 in relatives of the first line of kinship 0 points are assigned, if the fact of lack of physical activity is revealed during the survey, 1 point is assigned, in the presence of sufficient physical activity 0 points are assigned, when revealing the fact of the presence of an unbalanced diet 1 point is assigned, with a balanced diet 0 points are assigned, when identifying the age over 45 years old 1 point is assigned, under 45 years old 0 points are assigned, if there are more than 4 exacerbations of gout per year 1 point is assigned, if there are more less than 4 exacerbations of gout per year 0 points are assigned. The risk score for DM2 for each patient is calculated using the original mathematical expression (P). At values of P<0.5, there is a low risk of DM2; at values of 0.5 and above, there is a high risk of developing DM2.

EFFECT: method provides express risk assessment of DM2 development in patients with gout at any stage of patient observation.

1 cl, 1 dwg, 3 ex